SEARCH

SEARCH BY CITATION

References

  • 1
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 74550.
  • 2
    El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 81723.
  • 3
    Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterol 2004; 127: S516.
  • 4
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting the future healthcare burden from hepatitis C in the United States. Liver Transpl 2003; 9: 3318.
  • 5
    Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 77782.
  • 6
    Bruix J, Sherman M. AASLD Practice Guideline: management of hepatocellular carcinoma. Hepatology 2005; 42: 120836.
  • 7
    Sheu J-C, Sung J-L, Chen D-S, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 25966.
  • 8
    Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004; 127: S1047.
  • 9
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 6939.
  • 10
    Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004; 10: 3641.
  • 11
    Di Bisceglie AM, Order SE, Klein JL, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991; 86: 3358.
  • 12
    Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S1726.
  • 13
    Fottovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S3550.
  • 14
    Kudo M. Early detection and curative treatment of early stage hepatocellular carcinoma. Clin Gastroenterol Hepatol 2005; 3: S1448.
  • 15
    Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006; 141: 18190.
  • 16
    Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 12019.
  • 17
    Sangiovanni A, Del Ninno E, Fassani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma. Gastroenterology 2004; 126: 100514.
  • 18
    Sherman M. Alpha fetoprotein: an obituary. J Hepatol 2001; 34: 6035.
  • 19
    Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 5705.
  • 20
    Baron RL, Brancatelli G. Computed tomography imaging of hepatocellular carcinoma. Gastroenterology 2004; 127: S13343.
  • 21
    Taouli B, Losada M, Holland A, Krinsky G. Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 2004; 127: S14452.
  • 22
    Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 7584.